# Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

> **NCT05341349** · PHASE1 · TERMINATED · sponsor: **Emory University** · enrollment: 1 (actual)

## Conditions studied

- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Melanoma of Unknown Primary
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Melanoma
- Metastatic Mucosal Melanoma
- Metastatic Ocular Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Stereotactic Radiosurgery
- **PROCEDURE:** Tumor Treating Fields Therapy

## Key facts

- **NCT ID:** NCT05341349
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-13
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05341349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05341349, "Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05341349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*